An innovative model of early ASD diagnosis in the primary care setting: Integrating clinical evaluation and biomarkers to improve diagnostic accuracy
An innovative model of early ASD diagnosis in the primary care setting: Integrating clinical evaluation and biomarkers to improve diagnostic accuracy
批准号:
10057793
负责人:
Brandon Keehn
金额:
$43.51万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-08-05 至 2023-08-04
关键词:
AcetylcholineAgeAge-MonthsAgreementAreaAttentionBehavioralBehavioral SymptomsBiological AssayBiological MarkersBiological ProcessBlinkingCategoriesChildChildhoodClassificationClinicClinicalClinical assessmentsCommunitiesComplexConsensusDevelopmentDiagnosisDiagnosticDiagnostic ServicesDiseaseDopamineEarly InterventionEarly identificationEvaluationEvidence based interventionFamilyFutureGeographyHealth systemIndianaIndividualInterventionKnowledgeLifeLinkLow incomeMeasurableMeasuresMethodsMinorityModelingMydriasisNational Institute of Mental HealthNatureNeuromodulatorNeuronal PlasticityNorepinephrineOutcomePatient CarePhenotypePopulation HeterogeneityProcessProtocols documentationProviderPublic HealthPupil light reflexResearchResearch PersonnelResearch PrioritySamplingSeriesShapesSpecialistStandardizationStimulusSymptomsSystemTestingTimeTravelUniversitiesWait Timeaccurate diagnosisautism diagnostic observation scheduleautism spectrum disorderautistic childrenbarrier to carebasebiobehaviorcare providersclinical biomarkerscommunity settingcost effectivediagnostic accuracyexperiencehigh riskimprovedimproved outcomeindexingindividual patientinnovationinterestlife time costmedical schoolsmedical specialtiesmultimodalitynovelnovel markerpopulation basedpotential biomarkerpreferenceprimary care settingresearch clinical testingrural familiesskillssocialsocial culturesocietal coststoolvisual tracking
中文摘要
项目总结/摘要
自闭症谱系障碍(ASD)的早期识别和随后的循证参与
干预措施与巨大的发展收益和较低的生命周期成本有关。尽管核心
症状出现在生命的第一年,全国ASD诊断的平均年龄是4到5岁,
对低收入、少数民族和农村家庭儿童的诊断更加滞后。因此,
一个关键的公共卫生需要开发和测试模型的准确,精简的社区为基础的ASD
诊断.迄今为止的大部分研究都集中在对基于社区的模式进行独立审查上
早期ASD诊断和潜在生物过程的测量作为替代方法,
识别自闭症儿童然而,考虑到ASD表型的异质性以及
标准诊断工具的局限性,整合临床和生物行为的多方法方法
这些措施可能对提高社区ASD诊断的准确性产生最大的影响
设置.我们的目标是测试一种创新的ASD诊断方法,该方法将临床评估和
在一个大的高风险社区转介样本中评估小学儿童的生物行为标志物
护理设置。我们提出了三个具体目标:1)评估早期评估(EE)的诊断准确性
社区初级保健环境中ASD诊断的中心模型,2)确定生物行为是否
标记物可以可靠地区分在高危社区中有和没有ASD的幼儿
样本,以及3)确定临床和生物行为测量的组合是否可以用于
准确预测ASD诊断结果的高风险样本的幼儿评估的主要
护理设置。印第安纳州的EE中心将对120名16-30岁的儿童进行连续抽样
个月,由ASD专家使用标准化协议进行诊断确认,包括
自闭症诊断观察表-2以及发展水平和适应技能的措施。一
一系列眼动跟踪测量(瞳孔扩张、瞳孔对光反射、眨眼率、扫视潜伏期和注视
时间)将提供神经调质活性的间接测量(即,去甲肾上腺素乙酰胆碱
多巴胺)和非社会注意力脱离效率和社会偏好
与非社会性刺激相比。我们的方法展示了高水平的科学创新,因为它
整合临床评估和生物行为标记物测定,以开发和测试早期
ASD诊断在当地初级保健机构。这项研究之所以重要,是因为它有可能
为了减少ASD初次诊断的等待时间,并允许更早地进入循证干预,
从而改善儿童的预后并降低与该疾病相关的社会成本。未来这些
临床和生物行为特征可用于预测个体对干预的反应,
从而为干预分配提供了更精确和成本效益更高的方法。
英文摘要
Project Summary / Abstract
Early identification of autism spectrum disorder (ASD) and subsequent engagement in evidence-based
interventions is associated with substantial developmental gains and lower lifetime costs. Despite core
symptoms emerging in the first year of life, the national average age of ASD diagnosis is not until 4 to 5 years,
with diagnosis of children from lower income, minority, and rural families lagging further behind. Thus, there is
a critical public health need to develop and test models of accurate, streamlined community-based ASD
diagnosis. Much of the research to date has focused on independent examination of community-based models
of early ASD diagnosis and measures of underlying biological processes as alternative approaches to
identifying children with ASD. However, given the heterogeneous nature of the ASD phenotype as well as
limitations in standard diagnostic tools, multi-method approaches that integrate clinical and biobehavioral
measures are likely to have the most impact on advancing the accuracy of ASD diagnosis in the community
setting. Our objective is to test an innovative method of ASD diagnosis that integrates clinical evaluation and
assessment of biobehavioral markers in a large high-risk community-referral sample of children in the primary
care setting. We propose three specific aims: 1) Evaluate the diagnostic accuracy of the Early Evaluation (EE)
Hub model of ASD diagnosis in the community primary care setting, 2) Determine whether biobehavioral
markers can reliably differentiate young children with and without ASD in a high-risk community referred
sample, and 3) Determine whether a combination of clinical and biobehavioral measures can be used to
accurately predict ASD diagnostic outcome in a high-risk sample of young children evaluated in the primary
care setting. EE Hubs across the state of Indiana will refer a consecutive sample of 120 children, ages 16-30
months, for diagnostic confirmation by an expert ASD-specialist using a standardized protocol including the
Autism Diagnostic Observation Schedule – 2 as well as measures of developmental level and adaptive skills. A
series of eye-tracking measures (pupil dilation, pupillary light reflex, blink rate, saccadic latency, and looking
time) will provide indirect measures of neuromodulator activity (i.e., norepinephrine, acetylcholine, and
dopamine, respectively) and non-social attentional disengagement efficiency and preferences for social
compared to non-social stimuli. Our approach demonstrates a high level of scientific innovation because it
integrates both clinical evaluation and assays of biobehavioral markers to develop and test a model of early
ASD diagnosis in local primary care settings. The proposed research is significant because it has the potential
to decrease wait times for initial ASD diagnosis and allow for earlier entry into evidence-based interventions,
thereby improving child outcomes and reducing societal costs associated with the disorder. In the future, these
clinical and biobehavioral profiles could be used to predict how an individual may respond to interventions,
allowing for a more precise and cost effective method for intervention allocation.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
COVID-19 Pandemic Highlights Access Barriers for Children with Autism Spectrum Disorder.
COVID-19 疫情凸显了自闭症谱系障碍儿童的获取障碍。
DOI:
10.1097/dbp.0000000000000988
发表时间:
2021
期刊:
Journal of developmental and behavioral pediatrics : JDBP
影响因子:
--
作者:
[McNallyKeehn,Rebecca, Tomlin,Angela, Ciccarelli,MaryR]
通讯作者:
Ciccarelli,MaryR
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
芹菜素通过AGE-RAGE通路抑制干眼的炎症与氧化应激
-
批准号:82505677
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.00万元
-
批准年份:2025
-
负责人:吕雨霏
-
依托单位:
麝香通心滴丸通过干预AGE-RAGE轴调节O-GlcNAc修饰发挥防治DCM作用的药效物质及机制研究
-
批准号:82574874
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2025
-
负责人:刘天华
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位: